TG Therapeutics CEO to Present at Goldman Sachs Healthcare Conference
Event summary
- TG Therapeutics CEO Michael S. Weiss to participate in Goldman Sachs 47th Annual Healthcare Conference on June 9, 2026.
- Fireside chat scheduled for 2:00 PM ET at Loews Miami Beach Hotel.
- Live webcast available on TG Therapeutics' Investors & Media page.
- TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with FDA approval for BRIUMVI® in relapsing MS.
- Company also has regulatory approvals for BRIUMVI® outside the U.S.
The big picture
TG Therapeutics' participation in the Goldman Sachs Healthcare Conference underscores its strategic focus on expanding the commercial reach of BRIUMVI®, its approved treatment for relapsing MS. The event provides a platform to engage with key stakeholders and highlight the company's pipeline in B-cell diseases. As the biotech sector continues to evolve, TG Therapeutics' ability to navigate regulatory landscapes and market dynamics will be critical to its long-term success.
What we're watching
- Commercial Strategy
- How TG Therapeutics will leverage the conference to highlight BRIUMVI's market potential and expansion plans.
- Regulatory Dynamics
- Whether the company can secure additional regulatory approvals to bolster its commercial portfolio.
- Investor Sentiment
- The impact of the presentation on investor confidence and potential stock performance.